Hillstream Biopharma Current Valuation vs. Book Value Per Share

HILSDelisted Stock  USD 0.39  0.01  2.50%   
Based on the key profitability measurements obtained from Hillstream Biopharma's financial statements, Hillstream Biopharma may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in January. Profitability indicators assess Hillstream Biopharma's ability to earn profits and add value for shareholders.
For Hillstream Biopharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Hillstream Biopharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Hillstream Biopharma utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Hillstream Biopharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Hillstream Biopharma over time as well as its relative position and ranking within its peers.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
Please note, there is a significant difference between Hillstream Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Hillstream Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hillstream Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Hillstream Biopharma Book Value Per Share vs. Current Valuation Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Hillstream Biopharma's current stock value. Our valuation model uses many indicators to compare Hillstream Biopharma value to that of its competitors to determine the firm's financial worth.
Hillstream Biopharma is rated below average in current valuation category among its peers. It is rated below average in book value per share category among its peers . The ratio of Current Valuation to Book Value Per Share for Hillstream Biopharma is about  2,713,978 . Comparative valuation analysis is a catch-all technique that is used if you cannot value Hillstream Biopharma by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Hillstream Current Valuation vs. Competition

Hillstream Biopharma is rated below average in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is currently estimated at about 146.04 Million. Hillstream Biopharma adds roughly 496,658 in current valuation claiming only tiny portion of equities under Health Care industry.

Hillstream Book Value Per Share vs. Current Valuation

Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Hillstream Biopharma

Enterprise Value

 = 

Market Cap + Debt

-

Cash

 = 
496.66 K
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.

Hillstream Biopharma

Book Value per Share

 = 

Common Equity

Average Shares

 = 
0.18 X
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.

Hillstream Book Value Per Share Comparison

Hillstream Biopharma is currently under evaluation in book value per share category among its peers.

Hillstream Biopharma Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Hillstream Biopharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Hillstream Biopharma will eventually generate negative long term returns. The profitability progress is the general direction of Hillstream Biopharma's change in net profit over the period of time. It can combine multiple indicators of Hillstream Biopharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death for the treatment resistant cancers. The company was incorporated in 2017 and is based in Bridgewater, New Jersey. Hillstream Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 1 people.

Hillstream Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Hillstream Biopharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Hillstream Biopharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Hillstream Biopharma's important profitability drivers and their relationship over time.

Learn to be your own money manager

Our tools can tell you how much better you can do entering a position in Hillstream Biopharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run FinTech Suite Now

   

FinTech Suite

Use AI to screen and filter profitable investment opportunities
All  Next Launch Module

Use Investing Themes to Complement your Hillstream Biopharma position

In addition to having Hillstream Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Medical Equipment Thematic Idea Now

Medical Equipment
Medical Equipment Theme
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Medical Equipment theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Medical Equipment Theme or any other thematic opportunities.
View All  Next Launch
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.

Other Consideration for investing in Hillstream Stock

If you are still planning to invest in Hillstream Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Hillstream Biopharma's history and understand the potential risks before investing.
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
CEOs Directory
Screen CEOs from public companies around the world
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules